Multicenter Phase II Study of FOLFOX Plus Bi-weekly Cetuximab as First Line Treatment in Patients with Metastatic Colorectal Cancer

ABSTRACT: Interventions: Chemotherapy regimen mFOLFOX6 +Cetuximab Cetuximab 500mg/m2/biweekly Oxaliplatin 85mg/m2/biweekly l-LV 200mg/m2/biweekly 5-FU/bolus 40mg/m2/biweekly 5-FU/infusional 2400mg/m2/biweekly ( day1-3:46h) Primary outcome(s): Response Rate Study Design: Single arm Non-randomized

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 2621834 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR